While the drug demonstrated clinical promise by achieving a mean weight loss of up to 11% by week 50 and lowering HbA1c levels in type 2 diabetes patients by 1.5% to 1.7%, the physical toll on participants proved substantial. Data from week 44 showed nausea affecting approximately 70% of subjects, with vomiting rates reaching 69% and diarrhea impacting up to 37% of the cohort. No liver safety signals emerged during the study, providing a rare bright spot in the trial results.

Chief Medical Officer Scott Wasserman remains optimistic, framing the small-molecule oral treatment as a potentially more scalable and accessible alternative to current injectable therapies. The company is now pivoting focus toward a global Phase 2 trial for its KAI-7535 candidate. Results from that study are not expected until 2027, leaving shareholders to wait several years for further clarity on the drug's commercial viability.